Poolbeg Pharma signs option agreement to acquire orphan drug candidate
LONDON, UK: Poolbeg Pharma (AIM: POLB) has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX) for the treatment of oral ulcers in…